Humana Inc.

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Humana Beats Q1 Earnings Estimates on Increasing Premiums

AI-generated analysis

πŸ“ˆ Humana reported Q1 2026 adjusted earnings of $10.31 per share, exceeding analyst estimates by 3.5%.

⚠️ Net income declined 4.7% year over year to $1.2 billion due to falling premiums and rising expenses.

πŸ“‰ Total revenue increased 23.5% year over year to $39.6 billion, driven by premium gains and membership growth.

πŸ’Š The CenterWell segment contributed strongly with a revenue jump supported by its primary care business.

βš–οΈ The benefit ratio deteriorated 240 basis points year over year to 89.4% due to higher costs and benefits.

πŸ“‰ Operating expenses rose 25.9% year over year to $37.9 billion, impacting the bottom line despite revenue growth.

πŸ₯ Total medical membership grew 19.4% year over year to 17.7 million as of March 31, 2026.

πŸ’° Humana holds $5 billion in cash and cash equivalents, a 17.9% increase from the end of 2025.

πŸ“‰ Debt to capitalization deteriorated by 190 basis points to reach 43% at the end of the quarter.

πŸ”„ Management expects Individual Medicare Advantage membership to grow around 25% in 2026.

πŸ’Έ The company repurchased $107 million in shares and paid $107 million in dividends during Q1.

πŸ“‰ GAAP EPS guidance has been lowered, with new projections indicating a decline from the 2025 figure.

🏦 Investment income fell slightly year over year but still beat analyst consensus estimates.

🧾 Adjusted operating income dropped 8.8% year over year to $1.4 billion amid rising benefit costs.

πŸ“‰ Zacks currently maintains a Rank #5 (Strong Sell) rating for Humana Inc.

Bullish Signals
  • Humana reported first-quarter 2026 adjusted earnings of $10.31 per share, beating the Zacks Consensus Estimate by 3.5%.
  • Revenues improved 23.5% year over year to $39.6 billion, surpassing the consensus mark by 0.5%.
  • The CenterWell segment demonstrated robust performance with a revenue jump driven by its primary care business.
  • Medical membership increased to 17.7 million, rising 19.4% year over year and beating both analyst and internal estimates.
  • Cash and cash equivalents grew 17.9% year over year to $5 billion as of March 31, 2026.
  • Humana generated net cash from operations of $1.3 billion in the quarter, an increase of nearly fourfold from the prior year.
  • The company executed a share buyback of $107 million and paid dividends of $107 million during the first quarter.
  • Management projects total revenues to reach a minimum of $160 billion for the full year, implying a 23.4% increase.
  • Individual Medicare Advantage membership is expected to grow by around 25% in 2026.
  • The Insurance segment benefits from improved Medicare Advantage benchmark funding and a higher Part D direct subsidy tied to the IRA.
Risk Factors
  • The bottom line fell 11% year over year despite beating earnings estimates.
  • Operating expenses increased 25.9% year over year to $37.9 billion, driven by higher benefits and operating costs.
  • The benefit ratio deteriorated significantly, worsening by 240 basis points year over year to 89.4%.
  • Adjusted operating income dropped 8.8% year over year to $1.4 billion due to the deteriorating benefit ratio.
  • Within the CenterWell segment, adjusted operating income plummeted 25.1% year over year to $338 million.
  • The CenterWell unit's operating cost ratio deteriorated by 340 basis points to 94.5% due to v28 risk model implementation and higher pharmacy volumes.
  • GAAP EPS projections now indicate a sharp 47.5% decline from the 2025 figure, with adjusted EPS expected at least $9.00 versus prior guidance.
  • The stock carries a Zacks Rank #5 (Strong Sell) rating, signaling significant downside risk.
  • Long-term debt to capitalization deteriorated year over year, increasing leverage ratio by 190 basis points to 43%.
Full Analysis
Humana Inc. reported first-quarter 2026 adjusted earnings of $10.31 per share, which exceeded the Zacks Consensus Estimate by 3.5%, despite a year-over-year decline in the bottom line of 11%. Revenues demonstrated strong growth, increasing 23.5% year over year to reach $39.6 billion and surpassing the consensus mark by 0.5%. This performance was driven primarily by gains in premiums and robust results from the CenterWell segment, which saw a revenue jump bolstered by its primary care business. Additionally, an increase in overall medical membership contributed positively to the company's top line, though this growth was partially offset by rising operating expenses and a deteriorating benefit ratio. Humana’s total premiums advanced 23.6% year over year to $37.7 billion, significantly beating both the Zacks Consensus Estimate of $37.3 billion and internal estimates of $36.6 billion. Services revenues rose 25.7% to $1.7 billion, while investment income totaled $262 million, down 0.8% year over year but still meeting consensus expectations. The company's adjusted operating cost ratio improved to 10%, a gain of 50 basis points year over year, even as total operating expenses increased 25.9% to $37.9 billion due to higher benefits and costs. However, the benefit ratio deteriorated 240 basis points to 89.4%, and net income fell 4.7% to $1.2 billion. In its financial update as of March 31, 2026, Humana exited the quarter with cash and cash equivalents of $5 billion, an increase of 17.9% from the end of 2025, and total assets grew 13% to $55.3 billion. Long-term debt stood at $12.3 billion, leading to a debt-to-capitalization ratio that deteriorated to 43%. The company generated $1.3 billion in net cash from operations, which nearly quadrupled the previous year's figure. During the quarter, Humana engaged in share buybacks worth $107 million and paid dividends of $107 million. Looking ahead, Humana projects annual revenues of a minimum of $160 billion and adjusted EPS of at least $9.00, while anticipating continued growth in Individual Medicare Advantage membership by approximately 25% for 2026.